Lex­i­con dives ‘in­to the dark’ days fol­low­ing heart fail­ure hos­pi­tal­iza­tions with new cam­paign

Stud­ies have shown that for heart fail­ure pa­tients, the pe­ri­od af­ter leav­ing the hos­pi­tal is a risky time for re­cur­rence. Lex­i­con Phar­ma­ceu­ti­cals wants health­care providers to be aware of that, and in par­tic­u­lar the “dark and dan­ger­ous” first 30 days af­ter pa­tients are dis­charged from the hos­pi­tal.

Its new dis­ease aware­ness cam­paign, called “In­to the Dark,” launched at the Amer­i­can Col­lege of Car­di­ol­o­gy (ACC) con­fer­ence on Sat­ur­day, the same day Lex­i­con pre­sent­ed Phase III da­ta analy­ses of its can­di­date, dual SGLT1 and 2 in­hibitor so­tagliflozin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER